training & ktee
OUTCOMES & IMPACTS
A LEGACY OF LEARNING
and of creating new clinical & research capacity in Canada
AllerGen’s investment in capacity building among the next generation of leaders in the field of asthma and allergy has been one of the Network’s most impactful and transformational achievements.
From 2005 to 2019, AllerGen invested $26.4 million in its Highly Qualified Personnel (HQP) program ($22.3 million in research support and $4.1 million in specialized awards, grants and Fellowships) to provide advanced education, training and networking opportunities to 1,763 Network trainees, research staff and early-career professionals.
No Data Found
Transformational outcomes of AllerGen’s HQP and capacity-building programs include:
- HQP delivered 962 oral, poster and conference/scientific meeting presentations.
- at least 328 of AllerGen’s HQP graduates are now employed across sectors;
- 74 HQP secured faculty positions in Canada and abroad;
- $1.25 million was invested in support of five outstanding early-career clinician-scientists; and
- 53% of the Network’s 6,730 scientific publications have a trainee as first author.
THEN & NOW
AllerGen HQP share their stories
Testimonials by former AllerGen HQP about the impact on their careers of their involvement with the Network.
A LEGACY OF KNOWLEDGE
and of enhancing researchers’ innovation & communication skills
AllerGen’s research has been disseminated world-wide in publications, presentations, and various knowledge mobilization (KMb) tools and products geared to different receptor communities.
AllerGen’s knowledge mobilization and commercialization activities – including its investments in building Knowledge and Technology Exchange and Exploitation (KTEE) literacy and skills among its researchers and trainees – have accelerated the uptake and application of Network research outputs by diverse audiences and stakeholders.
Impacts & outputs of AllerGen’s KTEE activities and related capacity-building efforts include:
- over 6,700 scientific publications;
- 60 novel KTEE products and tools supporting patients, clinicians, educators, policymakers, advocacy groups and the general public;
- $3.7M invested in 83 KMb and commercialization initiatives;
- 85 Canadian innovations – including numerous patents, spin-off companies, industry licenses, and resources; and
- capacity-building webinars benefiting 432 attendees.
A LEGACY OF MENTORING
and of strengthening mentorship capacity in Canada
Mentorship among Network members – between peers; between different generations of scientists at different career levels; and between researchers and collaborators with other areas of expertise – has been a hallmark of AllerGen’s network way of working and a key to its success.
Beginning in 2018, AllerGen began formally recognizing, with a unique mentorship recognition awards program, this established tradition of mentorship within the Network; at the same time, it initiated a granting program to promote and enhance mentorship skills within the allergic/immune disease community. These initiatives persist, continuing beyond the end of the Network’s NCE mandate.
Contributions to the acknowledgement and promotion of mentorship by AllerGen include:
- establishment of an on-going, stakeholder-supported mentorship recognition and capacity-building program with a growing profile;
- 3 Lifetime Mentorship Achievement awards issued recognizing a sustained, career-spanning commitment to excellence in mentoring in allergic disease research and education;
- 14 Mentorship Achievement awards issued recognizing mentorship by researchers, trainees, community workers, and others active in the allergic/immune disease field; and
- 5 Mentorship Development Grants issued to support training – by researchers, trainees, and other professionals – in mentorship, leadership and related skills.